Under the terms of the agreement, Mitsubishi Tanabe Pharma has obtained exclusive rights to develop and commercialize EnVivo’s alpha-7 nicotinic acetylcholine receptor agonists such as EVP-6124 in Japan,
Archemix, a biotechnology company, has initiated a Phase IIa clinical trial of its anti-von Willebrand Factor aptamer, ARC1779. The trial is designed to evaluate the safety and efficacy
With this agreement, Eisai obtained the exclusive rights for development and marketing of Urief in 10 ASEAN (Association of South East Asian Nations) countries, as well as India
The agreement provides Sophysa with the rights to sell in Belgium and Luxembourg, and includes minimum purchase requirements. According to Misonix, the SonaStar is used by neuro and
According to Surgical Information Systems (SIS), Nebraska Orthopaedic Hospital chose SIS Anesthesia because of the system’s capacity to increase efficiencies through the reduction of documentation time and cost
Dr Adashi, a physician-scientist-executive with over 25 years of experience in healthcare and in the life sciences was also appointed to serve as a member of the board’s
Regeneron Pharmaceuticals, a biopharmaceutical company, has initiated patient enrollment in the Phase III program evaluating the efficacy and safety of Arcalyst, also known as interleukin-1 trap, in the
Under the terms of the agreement, Altea Therapeutics has granted Lilly and Amylin exclusive worldwide rights to develop and commercialize transdermal exenatide utilizing the Altea Therapeutics proprietary PassPort
The alliance allows Patheon and Kemwell to refer and market each others’ services to clients to better meet their respective client’s requirements. The alliance is effective immediately and
Arena Pharmaceuticals has announced positive top-line results from Bloom, the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management. Statistical significance (p<0.0001)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.